Omya announced that results of a recent in vitro study that compared the bioavailability of its newly developed source of calcium, Omyaforte 100, with other frequently used calcium salts.
Omya (Oftringen, Switzerland) announced that results of a recent in vitro study that compared the bioavailability of its newly developed source of calcium, Omyaforte 100, with other frequently used calcium salts, namely calcium citrate tetrahydrate, tri-calcium phosphate, and calcium carbonate. According to the study, Omyaforte exhibited a higher percentage of elemental calcium and excellent bioavailability compared to the other calcium sources.
The ingredient is a modified calcium carbonate with hydroxyapatite. According to the researchers, the ingredient’s performance can be attributed to the amorphous structure of the hydroxyapatite, which when combined with calcium carbonate creates greater porosity, lower agglomerates, and particle size to improve the solubility of calcium.
Because of its innovative composition and structure, says Omya, Omyaforte 100 is well-suited to applications with a high content of bioavailable calcium such as bone health mixtures, rehydration solutions and other powdered supplements. It can also be combined with a broad range of other bone health ingredients such as vitamin D and biopeptides. Therefore, the new mineral solution is ideal for athletes and “healthy agers” alike, as well as those who are avoiding dairy in their diet.
Reference